Form 4: Adaptive Biotechnologies COO Sells Shares
Insider Transaction (Form 4)
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold 35,228 shares of common stock on November 11, 2026.
Summary
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on November 11, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 4,983 Common Stock at $30.29 ($150,935) on November 11, 2026; holds 384,700 after (Direct).
- Open-market sale: disposed of 6,898 Common Stock at $31.22 ($215,356) on November 11, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,881 Common Stock at $12.14 ($144,235) on November 12, 2026; holds 389,683 after (Direct).
- Open-market sale: disposed of 11,881 Common Stock at $29.40 ($349,301) on November 12, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: acquired 11,466 Common Stock at $12.14 ($139,197) on November 13, 2026; holds 389,268 after (Direct).
- Open-market sale: disposed of 11,466 Common Stock at $28.93 ($331,711) on November 13, 2026; holds 377,802 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on November 11, 2026; holds 23,347 after (Direct).
- Option exercise/conversion: disposed of 11,881 Stock Option (right to buy) on November 12, 2026; holds 11,466 after (Direct).
- Option exercise/conversion: disposed of 11,466 Stock Option (right to buy) on November 13, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,047,303 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Julie Rubinstein — Officer (President and COO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-11 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-11-11 | Open-market sale | Common Stock | 4,983 | $30 | $150.9K | 384,700 |
| 2026-11-11 | Open-market sale | Common Stock | 6,898 | $31 | $215.4K | 377,802 |
| 2026-11-12 | Option exercise/conversion | Common Stock | 11,881 | $12 | $144.2K | 389,683 |
| 2026-11-12 | Open-market sale | Common Stock | 11,881 | $29 | $349.3K | 377,802 |
| 2026-11-13 | Option exercise/conversion | Common Stock | 11,466 | $12 | $139.2K | 389,268 |
| 2026-11-13 | Open-market sale | Common Stock | 11,466 | $29 | $331.7K | 377,802 |
| 2026-11-11 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 23,347 |
| 2026-11-12 | Option exercise/conversion | Stock Option (right to buy) | 11,881 | — | — | 11,466 |
| 2026-11-13 | Option exercise/conversion | Stock Option (right to buy) | 11,466 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-11 | Option exercise/conversion (11,881 shares) |
| 2026-11-11 | Open-market sale (4,983 shares) |
| 2026-11-11 | Open-market sale (6,898 shares) |
| 2026-11-12 | Option exercise/conversion (11,881 shares) |
| 2026-11-12 | Open-market sale (11,881 shares) |
| 2026-11-13 | Option exercise/conversion (11,466 shares) |
| 2026-11-13 | Open-market sale (11,466 shares) |
| 2026-11-11 | Option exercise/conversion (11,881 shares) |
| 2026-11-12 | Option exercise/conversion (11,881 shares) |
| 2026-11-13 | Option exercise/conversion (11,466 shares) |
Keywords
insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Julie Rubinstein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.